Development and study of a novel anti-HER2 therapeutic conjugate based on DARPin G3
Introduction. Overexpression of human epidermal growth factor receptor 2 (HER2) is a critical driver of malignancy in multiple solid tumors, underscoring the demand for innovative targeted therapeutics. Protein–drug conjugates offer selective delivery of highly potent cytotoxic payloads directly to tumor cells. Desi...